Last reviewed · How we verify
Terbutaline Infusion
Terbutaline is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Terbutaline is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Acute bronchospasm and reversible airway obstruction in asthma and COPD, Premature labor (tocolytic use, though less common in modern practice).
At a glance
| Generic name | Terbutaline Infusion |
|---|---|
| Sponsor | Muhammad Aamir Latif |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Terbutaline binds to and activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, rapidly relieving airway obstruction. When given as an infusion, it provides sustained systemic delivery for acute bronchospasm management.
Approved indications
- Acute bronchospasm and reversible airway obstruction in asthma and COPD
- Premature labor (tocolytic use, though less common in modern practice)
Common side effects
- Tremor
- Tachycardia
- Headache
- Palpitations
- Nervousness/anxiety
- Muscle cramps
Key clinical trials
- Hot Flashes and Neurovascular Function in Women (NA)
- Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma (PHASE3)
- Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure (PHASE4)
- In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
- Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia (PHASE4)
- Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia (NA)
- Intravenous Terbutaline in Severe Status Asthmaticus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terbutaline Infusion CI brief — competitive landscape report
- Terbutaline Infusion updates RSS · CI watch RSS
- Muhammad Aamir Latif portfolio CI